Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.9MCash on Hand
0.8mo Cash Runway
Follow HURA by emailGet an email when HURA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HURA, unsubscribe in one click. Privacy
📣 What HURA Says Is Next
this year · “This agreement allows us to fund operations through anticipated key milestones this year and beyond through anticipated top-line Phase 3 results of our lead IFx-2.0 program.”
Company press release, Apr 22, 2026 · SEC filing
mid-2027 · “Our IFx-2.0 Phase 3 study in front-line Merkel Cell Carcinoma (MCC) continues to enroll, and we now anticipate completing enrollment in mid-2027.”
Company press release, Apr 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 results: cash of $1.9 million at September 30, 2026, after $9.2 million gross proceeds on the Parkview credit facility. R&D expenses were $3.7 million versus $5.0 million, and G&A was $2.0 million versus $1.6 million. Form 8-K · SEC filing · Press release
Nov 6, 2026 ·
Financing TuHURA Biosciences borrowed an additional $1,500,000 on November 2, 2026 under its revolving credit facility with Parkview Holdings One LLC, to be used for general corporate purposes. The facility matures April 21, 2031, with maximum availability of $50 million. Form 8-K · SEC filing
Oct 16, 2026 ·
Financing TuHURA Biosciences borrowed an additional $650,000 on October 9, 2026 under its revolving credit facility with Parkview Holdings One LLC, which has a maximum availability of $50 million and matures April 21, 2031. The company expects to use the funds for general corporate purposes. Form 8-K · SEC filing
Sep 24, 2026 ·
Financing TuHURA Biosciences borrowed an additional $650,000 on September 21, 2026 under its revolving credit facility with Parkview Holdings One LLC, which has up to $50 million in availability and matures April 21, 2031. The funds are for general corporate purposes. Form 8-K · SEC filing
Sep 17, 2026 ·
TuHURA amended its September 16, 2026 8-K to clarify its 2026 Inducement Equity Incentive Plan, adopted September 10, 2026 without stockholder approval. The plan reserves 5,000,000 shares for new-employee equity awards, none granted yet, expected as stock options priced at or above the closing price. Form 8-K/A · SEC filing
Sep 17, 2026 ·
Financing TuHURA Biosciences borrowed an additional $650,000 on September 14, 2026 under its revolving credit facility with Parkview Holdings One LLC, which has a maximum availability of $50 million and matures April 21, 2031. The company expects to use the funds for general corporate purposes. Form 8-K · SEC filing
Sep 16, 2026 ·
Leadership Board adopted the 2026 Inducement Equity Incentive Plan on September 10, 2026, reserving 5,000,000 shares of common stock for equity awards to new employees without stockholder approval under Nasdaq Rule 5635(c)(4). Only nonqualified awards are permitted. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2027 · Phase 2/3 · Recruiting · Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma Registry primary completion date, not a results date
Apr 2027 · Phase 1 · Recruiting · IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) Registry primary completion date, not a results date
Dec 2028 · Phase 1/2 · Upcoming Trial · A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not HURA's own candidates): Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
HURA holds $1.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.8M/quarter from operations,
an estimated runway of 0.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:74 · High
Cash runway 1 months +40
ATM program on file since Apr 2026 +15
Shelf registration (S-3, Nov 2025) +10
Company says cash lasts into 2028 -5The Company expects that its existing capital resources, including the future expected cash proceeds from the Parkview Credit Facility, will be sufficient to fund the Company’s planned future operations into 2028.10-Q, Nov 2026
Share count 65,758,417 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full HURA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HURA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.